Helius Medical Technologies, Inc. to Release Second Quarter of Fiscal Year 2021 Financial Results on August 12, 2021
June 30 2021 - 7:30AM
Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius”
or the “Company”), a neurotech company focused on neurological
wellness, today announced that second quarter of fiscal year 2021
financial results will be released after the market closes on
Thursday, August 12th.
Management will host a conference call at 5:00
p.m. Eastern Time on August 12th to discuss the results of the
quarter. Those who would like to participate may dial 877-407-2988
(201-389-0923 for international callers) and provide access code
13721027. A live webcast of the call will also be provided on the
Events section of the Company's investor relations website and can
be accessed directly via the following link:
https://78449.themediaframe.com/dataconf/productusers/hls/mediaframe/44540/indexl.html.
For those unable to participate, a replay of the
call will be available for two weeks at 877-660-6853 (201-612-7415
for international callers); access code 13721027. The webcast will
be archived on the Events section of the Company’s investor
relations website.
About Helius Medical Technologies,
Inc.
Helius Medical Technologies is a neurotech
company focused on neurological wellness. The Company’s purpose is
to develop, license and acquire unique and non-invasive platform
technologies that amplify the brain’s ability to heal itself. The
Company’s first commercial product is the Portable Neuromodulation
Stimulator (PoNSTM). For more information,
visit www.heliusmedical.com.
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNSTM)
is an innovative non-surgical device, inclusive of a controller and
mouthpiece, which delivers electrical stimulation to the surface of
the tongue to provide treatment of gait deficit. The PoNS device is
indicated for use in the United States as a short term treatment of
gait deficit due to mild-to-moderate symptoms from multiple
sclerosis (“MS”) and is to be used as an adjunct to a supervised
therapeutic exercise program in patients 22 years of age and over
by prescription only. It is authorized for sale in Canada as a
class II, non-implantable, medical device intended as a short term
treatment (14 weeks) of gait deficit due to mild and moderate
symptoms from MS, and chronic balance deficit due to
mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used
in conjunction with physical therapy. PoNS is an investigational
medical device in the European Union (“EU”) and Australia (“AUS”).
It is currently under premarket review by the AUS Therapeutic Goods
Administration.
Investor Relations Contact:
Westwicke on behalf of Helius Medical Technologies, Inc.
Jack Powell, Vice President
investorrelations@heliusmedical.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2023 to Apr 2024